Denosumab Biosimilar - Research Grade

Target: RANKL.

Specificity: Detects human RANK Ligand. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Denosumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Denosumab biosimilar is a human IgG2 monoclonal antibody that binds to human RANKL. Denosumab has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.